Hero image

Oncology Policy Grant Program

Oncology Policy Grant Program

MSD Belgium is extending an open invitation to the research community in Belgium to apply for an unrestricted grant as part of the Oncology Policy Grant Program. This grant request, which will be issued publicly, will be for research projects aimed at analyzing policy and health system readiness to deliver sustainable and innovative cancer care.

To be eligible for applying for this grant, researchers and research teams must meet the following selection criteria:

This research will be funded by an unrestricted grant from MSD. Once the grant has been awarded, the researchers will remain independent and MSD will have no involvement in the direction of the research.

Please read this document carefully for further information about the themes, the application process, eligibility criteria and assessment criteria.

MSD’s Independent Oncology Policy Grant Program seeks to encourage research around the following themes:

  • What is the impact of cancer policies on cancer outcomes?
  • How can new approaches improve the financing of & access to cancer care?
  • How can cancer policies enable health equity in cancer care?

To be eligible for applying for this grant, researchers and research teams must meet the following selection criteria:

  • Come from an accredited local and/or regional academic institution
  • Have a proven track record in research in the cancer space
  • Have experience working in and researching health policy
  • Demonstrate ability to publish a quality, peer-reviewed publication within one year

The deadline for applying is May 18th, 2022. The application shall be sent via e-mail to MSD Global Oncology Policy at oncopolicy02@merck.com.

An open information session will be organized on May 3rd, 2022 at 11:00 AM. Queries can be directed to Jean-Yves Daxhelet, Policy Manager Oncology for MSD Belgium at jean-yves.daxhelet@merck.com.

However, MSD Belgium will NOT be involved in assessing and selecting grant applications; this will be done by the Global Oncology Policy team.